亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Novel Methods to Prevent and Treat Liver and Colon Cancer

技術優勢
Target gut microbiota and gut-liver axis Reversing the pathways that are abnormally occurred in both colon and liver cancer Early diagnosis Prevent by reducing inflammation and boost metabolism Cancer treatment
技術應用
Prevention and treatment of colon and liver cancer
詳細技術說明
The incidence of liver and colon cancer is rising due to obesity and metabolic syndrome. It has been found that the gut microenvironment is altered due to unhealthy diet in animals with dysbiosis, lack of nutrients, and dysregulated bile acid synthesis. Despite this correlation, most treatments for liver and colon cancer (such as a colectomy or chemotherapy) do not attempt to address the alteration of the gut microenvironment as a form of recovery. Researchers at the University of California, Davis have developed a method to treat colon and liver cancer by using retinoids and histone deacetylase inhibitors (HDAC inhibitors) using both natural compounds and synthetic chemicals. In addition, the researchers have uncovered novel mechanism for such anti-cancer effects. Retinoids and HDAC inhibitors can work through specific microRNAs (which are tumor suppressive) to induce apoptosis and arrest of liver and colon cancer cells. Additionally, they reduce inflammation and improve metabolism. The treatment has been successfully tested in vitro in human colon and liver cancer cells, ex vivo in human colon and liver biopsies and in vivo in specific knockout mice as well as xenograt tumor models.
*Abstract

Researchers at the University of California, Davis have developed a method to treat liver and colon cancer using natural or synthetic retinoids in combination with histone deacetylase inhibitors.

*IP Issue Date
May 17, 2018
*Principal Investigation

Name: Yu-Jui Yvonne Wan

Department:

其他

Related Materials

Fan Yang, Ying Hu, Hui-Xin Liu, and Yu-Jui Yvonne Wan MiR-22-silenced Cyclin A Expression in Colon and Liver Cancer Cells Is Regulated by Bile Acid Receptor J. Biol. Chem. 2015 290: 6507-. doi:10.1074/jbc.M114.620369


Tech ID/UC Case

27056/2016-363-0


Related Cases

2016-363-0

國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備